Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVAC NASDAQ:CYTK NASDAQ:TGTX NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$5.44+0.4%$5.44$2.37▼$5.72$1.22B2.53694,622 shs353,942 shsCYTKCytokinetics$38.34+0.8%$35.76$29.31▼$59.39$4.59B0.641.51 million shs1.55 million shsTGTXTG Therapeutics$29.44+2.3%$34.09$21.11▼$46.48$4.67B1.952.92 million shs2.18 million shsVKTXViking Therapeutics$26.00+1.3%$31.17$18.92▼$81.73$2.92B0.679.03 million shs10.55 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac0.00%-0.73%-0.37%+33.01%+64.35%CYTKCytokinetics0.00%-0.85%+3.12%+25.54%-33.11%TGTXTG Therapeutics0.00%+4.84%-20.22%-14.84%+20.36%VKTXViking Therapeutics0.00%-35.05%-24.46%-3.63%-59.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVACCureVac4.6437 of 5 stars4.15.00.04.91.60.01.3CYTKCytokinetics3.5973 of 5 stars3.51.00.04.62.70.80.0TGTXTG Therapeutics4.3618 of 5 stars3.41.00.03.53.12.51.9VKTXViking Therapeutics3.9735 of 5 stars3.51.00.04.72.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac 2.20Hold$6.8325.61% UpsideCYTKCytokinetics 2.93Moderate Buy$71.5886.71% UpsideTGTXTG Therapeutics 2.75Moderate Buy$46.2557.10% UpsideVKTXViking Therapeutics 3.00Buy$86.92234.32% UpsideCurrent Analyst Ratings BreakdownLatest CVAC, CYTK, VKTX, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.008/8/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $77.007/30/2025CYTKCytokineticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform7/24/2025VKTXViking TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetStrong-Buy ➝ Strong-Buy$125.00 ➝ $122.007/24/2025VKTXViking TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$31.00 ➝ $38.007/10/2025TGTXTG TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$37.006/26/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.506/25/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.006/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/12/2025CVACCureVacCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform6/12/2025CVACCureVacCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$579.18M2.11$0.87 per share6.23$3.36 per share1.62CYTKCytokinetics$18.47M248.39N/AN/A($1.15) per share-33.34TGTXTG Therapeutics$329M14.20$0.12 per share245.45$1.43 per share20.59VKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac$175.50M$0.965.67N/AN/A38.21%29.57%25.41%11/11/2025 (Estimated)CYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3779.5729.44N/A13.31%26.05%9.58%11/3/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest CVAC, CYTK, VKTX, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025CVACCureVac-$0.15-$0.30-$0.15-$0.30$4.27 million$1.41 million8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 million7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.056.176.16CYTKCytokineticsN/A6.766.76TGTXTG Therapeutics0.893.862.96VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%CYTKCytokineticsN/ATGTXTG Therapeutics58.58%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCVACCureVacN/ACYTKCytokinetics3.40%TGTXTG Therapeutics10.64%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac880224.34 millionN/AOptionableCYTKCytokinetics250119.66 million115.59 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableVKTXViking Therapeutics20112.44 million107.84 millionOptionableCVAC, CYTK, VKTX, and TGTX HeadlinesRecent News About These CompaniesViking Therapeutics, Inc. $VKTX Shares Sold by Charles Schwab Investment Management Inc.3 hours ago | marketbeat.com2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top AnalystsAugust 24 at 8:45 AM | fool.comIs Viking Therapeutics stock a bargain after this week’s sell-off?August 23 at 5:06 PM | msn.comAnalysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Price Target at $86.92August 23 at 3:59 AM | americanbankingnews.comViking Therapeutics (VKTX) Down 23.4% Since Last Earnings Report: Can It Rebound?August 22 at 4:37 PM | msn.comViking Therapeutics (VKTX) Reports Increased Net Losses For Second QuarterAugust 22 at 4:37 PM | finance.yahoo.comHere's Why Shares in Viking Therapeutics Crashed This WeekAugust 22 at 11:35 AM | msn.comViking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?August 21, 2025 | insidermonkey.comA Closer Look at Viking Therapeutics's Options Market DynamicsAugust 21, 2025 | benzinga.comPost Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?August 21, 2025 | zacks.comViking Therapeutics (NASDAQ:VKTX) Shares Gap Down - Time to Sell?August 21, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Viking Therapeutics (NASDAQ:VKTX)August 21, 2025 | marketbeat.comViking Therapeutics Sees Unusually High Options Volume (NASDAQ:VKTX)August 21, 2025 | marketbeat.comIs Beaten-Down Viking Therapeutics Stock a Buy on the Dip?August 21, 2025 | fool.comSteward Partners Investment Advisory LLC Acquires 13,626 Shares of Viking Therapeutics, Inc. $VKTXAugust 21, 2025 | marketbeat.comViking Therapeutics' (VKTX) Buy Rating Reiterated at HC WainwrightAugust 21, 2025 | americanbankingnews.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Buy" by AnalystsAugust 21, 2025 | marketbeat.comViking Therapeutics: Panic Creates OpportunityAugust 20, 2025 | seekingalpha.comHere's Why Viking Therapeutics Bounced Back TodayAugust 20, 2025 | fool.comViking Therapeutics (VKTX) Slashes 42% on Huge Clinical Study Dropout RateAugust 20, 2025 | insidermonkey.comViking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill StudyAugust 20, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVAC, CYTK, VKTX, and TGTX Company DescriptionsCureVac NASDAQ:CVAC$5.44 +0.02 (+0.37%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.41 -0.03 (-0.55%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Cytokinetics NASDAQ:CYTK$38.34 +0.29 (+0.76%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$39.15 +0.81 (+2.10%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.TG Therapeutics NASDAQ:TGTX$29.44 +0.67 (+2.33%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$29.48 +0.04 (+0.12%) As of 04:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Viking Therapeutics NASDAQ:VKTX$26.00 +0.34 (+1.33%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$25.95 -0.05 (-0.18%) As of 05:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access